Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16,785,250
-
Total 13F shares
-
285,765
-
Share change
-
+285,765
-
Total reported value
-
$2,714,943
-
Price per share
-
$9.50
-
Number of holders
-
15
-
Value change
-
+$2,714,945
-
Number of buys
-
15
Institutional Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q2 2023
As of 30 Jun 2023,
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
285,765 shares.
The largest 10 holders included
Nantahala Capital Management, LLC, VANGUARD GROUP INC, CM Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, MEYER HANDELMAN CO, BRIDGEWAY CAPITAL MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, Steward Partners Investment Advisory, LLC, UBS Group AG, and CITIGROUP INC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.